Cargando…

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy

Heart failure (HF) is a major cause of morbidity and mortality worldwide, highlighting an urgent need for novel treatment options, despite recent improvements. Aberrant Ca(2+) handling is a key feature of HF pathophysiology. Restoring the Ca(2+) regulating machinery is an attractive therapeutic stra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grote Beverborg, Niels, Später, Daniela, Knöll, Ralph, Hidalgo, Alejandro, Yeh, Steve T., Elbeck, Zaher, Silljé, Herman H. W., Eijgenraam, Tim R., Siga, Humam, Zurek, Magdalena, Palmér, Malin, Pehrsson, Susanne, Albery, Tamsin, Bomer, Nils, Hoes, Martijn F., Boogerd, Cornelis J., Frisk, Michael, van Rooij, Eva, Damle, Sagar, Louch, William E., Wang, Qing-Dong, Fritsche-Danielson, Regina, Chien, Kenneth R., Hansson, Kenny M., Mullick, Adam E., de Boer, Rudolf A., van der Meer, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405807/ https://www.ncbi.nlm.nih.gov/pubmed/34462437 http://dx.doi.org/10.1038/s41467-021-25439-0

Ejemplares similares

Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation
por: Eijgenraam, Tim R., et al.
Publicado: (2022)

Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del
por: Deiman, Frederik E., et al.
Publicado: (2022)

Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure
por: De Genst, Erwin, et al.
Publicado: (2022)

Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)–Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy
por: Eijgenraam, Tim R., et al.
Publicado: (2021)

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy
por: Eijgenraam, Tim R., et al.
Publicado: (2020)

Author Correction: The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy
por: Eijgenraam, Tim R., et al.
Publicado: (2020)

An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation
por: Rohner, Eduarde, et al.
Publicado: (2021)

Negative Adrenergic Feedback Specific to Phospholamban
por: Hasenfuss, Gerd, et al.
Publicado: (2017)

Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
por: te Rijdt, W. P., et al.
Publicado: (2021)

Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo
por: Pehrsson, Susanne, et al.
Publicado: (2019)

Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology
por: Alnuwaysir, Ridha I. S., et al.
Publicado: (2021)

Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?
por: Bomer, Nils, et al.
Publicado: (2022)

Prevalence and cardiac phenotype of patients with a phospholamban mutation
por: Hof, I. E., et al.
Publicado: (2018)

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers
por: de Brouwer, Remco, et al.
Publicado: (2023)

Immunoelectron microscopical localization of phospholamban in adult canine ventricular muscle
Publicado: (1987)

Localization of phospholamban in smooth muscle using immunogold electron microscopy
Publicado: (1988)

The role of CaMKII regulation of phospholamban activity in heart disease
por: Mattiazzi, Alicia, et al.
Publicado: (2014)

Phospholamban cardiomyopathy: a Canadian perspective on a unique population
por: Cheung, C. C., et al.
Publicado: (2019)

Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
por: Mundiña-Weilenmann, Cecilia Beatriz, et al.
Publicado: (2019)

Phospholamban R14del disease: The past, the present and the future
por: Vafiadaki, Elizabeth, et al.
Publicado: (2023)

Phospholamban pentamerization increases sensitivity and dynamic range of cardiac relaxation
por: Funk, Florian, et al.
Publicado: (2023)

Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Obesity does not Lead to Imbalance Between Myocardial Phospholamban Phosphorylation and Dephosphorylation
por: Freire, Paula Paccielli, et al.
Publicado: (2014)

Phospholamban overexpression in mice causes a centronuclear myopathy-like phenotype
por: Fajardo, Val A., et al.
Publicado: (2015)

Atomistic Structure and Dynamics of the Ca(2+)-ATPase Bound to Phosphorylated Phospholamban
por: Aguayo-Ortiz, Rodrigo, et al.
Publicado: (2020)

Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers
por: Koch, Daniel, et al.
Publicado: (2021)

Myofilament Alterations Associated with Human R14del-Phospholamban Cardiomyopathy
por: Kumar, Mohit, et al.
Publicado: (2023)

Targeting Cardiomyocyte Ca(2+) Homeostasis in Heart Failure
por: Røe, Åsmund T., et al.
Publicado: (2015)

Regulation of Cardiomyocyte T-Tubular Structure: Opportunities for Therapy
por: Manfra, Ornella, et al.
Publicado: (2017)

Co-Expression of SERCA Isoforms, Phospholamban and Sarcolipin in Human Skeletal Muscle Fibers
por: Fajardo, Val A., et al.
Publicado: (2013)

Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to enhance cardiac function
por: Keceli, Gizem, et al.
Publicado: (2019)

Sarcolipin deletion exacerbates soleus muscle atrophy and weakness in phospholamban overexpressing mice
por: Fajardo, Val A., et al.
Publicado: (2017)

Alterations of protein expression of phospholamban, ZASP and plakoglobin in human atria in subgroups of seniors
por: Gergs, Ulrich, et al.
Publicado: (2019)

A hallmark of phospholamban functional divergence is located in the N-terminal phosphorylation domain
por: Fernández-de Gortari, Eli, et al.
Publicado: (2020)

Structures of PKA–phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy
por: Qin, Juan, et al.
Publicado: (2022)

Phospholamban p.Arg14del Cardiomyopathy: A Japanese Case Series
por: Tabata, Tomoka, et al.
Publicado: (2021)

Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue Engineering
por: Hoes, Martijn F., et al.
Publicado: (2018)

High selenium levels associate with reduced risk of mortality and new‐onset heart failure: data from PREVEND
por: Al‐Mubarak, Ali A., et al.
Publicado: (2022)

An Allosteric Mechanism Inferred from Molecular Dynamics Simulations on Phospholamban Pentamer in Lipid Membranes
por: Lian, Peng, et al.
Publicado: (2011)

A Designed Zinc-finger Transcriptional Repressor of Phospholamban Improves Function of the Failing Heart
por: Zhang, H Steve, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dd9o5p625lrhu4cq4c284b1393